309 related articles for article (PubMed ID: 18949548)
1. Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2).
Stafforini DM
Cardiovasc Drugs Ther; 2009 Feb; 23(1):73-83. PubMed ID: 18949548
[TBL] [Abstract][Full Text] [Related]
2. Plasma PAF-AH (PLA2G7): Biochemical Properties, Association with LDLs and HDLs, and Regulation of Expression.
Stafforini DM
Enzymes; 2015; 38():71-93. PubMed ID: 26612648
[TBL] [Abstract][Full Text] [Related]
3. Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase.
Tselepis AD; John Chapman M
Atheroscler Suppl; 2002 Dec; 3(4):57-68. PubMed ID: 12573364
[TBL] [Abstract][Full Text] [Related]
4. Extracellular phospholipases in atherosclerosis.
Karabina SA; Gora S; Atout R; Ninio E
Biochimie; 2010 Jun; 92(6):594-600. PubMed ID: 20153800
[TBL] [Abstract][Full Text] [Related]
5. Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2.
Rosenson RS; Stafforini DM
J Lipid Res; 2012 Sep; 53(9):1767-82. PubMed ID: 22665167
[TBL] [Abstract][Full Text] [Related]
6. Circulating platelet-activating factor is primarily cleared by transport, not intravascular hydrolysis by lipoprotein-associated phospholipase A2/ PAF acetylhydrolase.
Liu J; Chen R; Marathe GK; Febbraio M; Zou W; McIntyre TM
Circ Res; 2011 Feb; 108(4):469-77. PubMed ID: 21183738
[TBL] [Abstract][Full Text] [Related]
7. Reduced PAF-acetylhydrolase activity associated with Lp(a) in patients with coronary artery disease.
Tsironis LD; Katsouras CS; Lourida ES; Mitsios JV; Goudevenos J; Elisaf M; Tselepis AD
Atherosclerosis; 2004 Nov; 177(1):193-201. PubMed ID: 15488884
[TBL] [Abstract][Full Text] [Related]
8. Human plasma platelet-activating factor acetylhydrolase binds to all the murine lipoproteins, conferring protection against oxidative stress.
Noto H; Hara M; Karasawa K; Iso-O N; Satoh H; Togo M; Hashimoto Y; Yamada Y; Kosaka T; Kawamura M; Kimura S; Tsukamoto K
Arterioscler Thromb Vasc Biol; 2003 May; 23(5):829-35. PubMed ID: 12649088
[TBL] [Abstract][Full Text] [Related]
9. Molecular basis for susceptibility of plasma platelet-activating factor acetylhydrolase to oxidative inactivation.
MacRitchie AN; Gardner AA; Prescott SM; Stafforini DM
FASEB J; 2007 Apr; 21(4):1164-76. PubMed ID: 17210780
[TBL] [Abstract][Full Text] [Related]
10. Plasma PAF-acetylhydrolase: an unfulfilled promise?
Karabina SA; Ninio E
Biochim Biophys Acta; 2006 Nov; 1761(11):1351-8. PubMed ID: 16807087
[TBL] [Abstract][Full Text] [Related]
11. Molecular characterization of the constitutive expression of the plasma platelet-activating factor acetylhydrolase gene in macrophages.
Wu X; McIntyre TM; Zimmerman GA; Prescott SM; Stafforini DM
Biochem J; 2003 Oct; 375(Pt 2):351-63. PubMed ID: 12854969
[TBL] [Abstract][Full Text] [Related]
12. Regulating inflammation through the anti-inflammatory enzyme platelet-activating factor-acetylhydrolase.
Castro Faria Neto HC; Stafforini DM; Prescott SM; Zimmerman GA
Mem Inst Oswaldo Cruz; 2005 Mar; 100 Suppl 1():83-91. PubMed ID: 15962103
[TBL] [Abstract][Full Text] [Related]
13. Maternal and fetal plasma platelet-activating factor acetylhydrolase activity and distribution in pre-eclampsia.
Fan P; Liu XH; He GL; Zhang S; Zhang JX; Bai H
Pediatr Res; 2012 Oct; 72(4):426-31. PubMed ID: 22797139
[TBL] [Abstract][Full Text] [Related]
14. Effect of lipoprotein (a) on platelet activation induced by platelet-activating factor: role of apolipoprotein (a) and endogenous PAF-acetylhydrolase.
Tsironis LD; Mitsios JV; Milionis HJ; Elisaf M; Tselepis AD
Cardiovasc Res; 2004 Jul; 63(1):130-8. PubMed ID: 15194469
[TBL] [Abstract][Full Text] [Related]
15. The effect of exenatide (a GLP-1 analog) and sitagliptin (a DPP-4 inhibitor) on plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and concentration in normal and fructose-fed rats.
Wójcicka G; Zaręba M; Warpas A; Jamroz-Wiśniewska A; Rusek M; Czechowska G; Bełtowski J
Eur J Pharmacol; 2019 May; 850():180-189. PubMed ID: 30768981
[TBL] [Abstract][Full Text] [Related]
16. Identification of a domain that mediates association of platelet-activating factor acetylhydrolase with high density lipoprotein.
Gardner AA; Reichert EC; Topham MK; Stafforini DM
J Biol Chem; 2008 Jun; 283(25):17099-106. PubMed ID: 18434304
[TBL] [Abstract][Full Text] [Related]
17. Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study.
Winkler K; Winkelmann BR; Scharnagl H; Hoffmann MM; Grawitz AB; Nauck M; Böhm BO; März W
Circulation; 2005 Mar; 111(8):980-7. PubMed ID: 15710755
[TBL] [Abstract][Full Text] [Related]
18. Novel mechanism for regulation of plasma platelet-activating factor acetylhydrolase expression in mammalian cells.
Gardner AA; Reichert EC; Alexander TS; Topham MK; Stafforini DM
Biochem J; 2010 May; 428(2):269-79. PubMed ID: 20331434
[TBL] [Abstract][Full Text] [Related]
19. PAF-acetylhydrolase activity in plasma of patients with chronic kidney disease. Effect of long-term therapy with erythropoietin.
Papavasiliou EC; Gouva C; Siamopoulos KC; Tselepis AD
Nephrol Dial Transplant; 2006 May; 21(5):1270-7. PubMed ID: 16421163
[TBL] [Abstract][Full Text] [Related]
20. New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease.
Tsimikas S; Tsironis LD; Tselepis AD
Arterioscler Thromb Vasc Biol; 2007 Oct; 27(10):2094-9. PubMed ID: 17626905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
